WO2009022652A1 - Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele - Google Patents

Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele Download PDF

Info

Publication number
WO2009022652A1
WO2009022652A1 PCT/JP2008/064317 JP2008064317W WO2009022652A1 WO 2009022652 A1 WO2009022652 A1 WO 2009022652A1 JP 2008064317 W JP2008064317 W JP 2008064317W WO 2009022652 A1 WO2009022652 A1 WO 2009022652A1
Authority
WO
WIPO (PCT)
Prior art keywords
hla
lck
positive
cancer
derived peptide
Prior art date
Application number
PCT/JP2008/064317
Other languages
French (fr)
Japanese (ja)
Inventor
Kyogo Itoh
Masanori Noguchi
Mamoru Harada
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurume University filed Critical Kurume University
Priority to JP2009528113A priority Critical patent/JP4972691B2/en
Publication of WO2009022652A1 publication Critical patent/WO2009022652A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is an Lck-derived peptide which is useful for the treatment or prevention of a cancer patient who is positive for an HLA-A3 supertype allele. Specifically disclosed are peptides of Lck90-99, Lck449-458 and Lck450-458 (SEQ ID NOs: 4, 17 and 18). These peptides can bind to an HLA-A3 supertype allele molecule and has a peptide-specific CTL-inducing ability. These peptides are particularly useful for the treatment of a cancer patient who is negative for an HLA-A2 or HLA-A24 molecule for which many cancer vaccine candidate peptides have been identified so far.
PCT/JP2008/064317 2007-08-16 2008-08-08 Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele WO2009022652A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009528113A JP4972691B2 (en) 2007-08-16 2008-08-08 Lck-derived peptide useful for cancer vaccine therapy for HLA-A3 supertype allele positive cancer patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007212179 2007-08-16
JP2007-212179 2007-08-16

Publications (1)

Publication Number Publication Date
WO2009022652A1 true WO2009022652A1 (en) 2009-02-19

Family

ID=40350705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064317 WO2009022652A1 (en) 2007-08-16 2008-08-08 Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele

Country Status (2)

Country Link
JP (1) JP4972691B2 (en)
WO (1) WO2009022652A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060235A1 (en) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 Novel four-ctl epitope-joined peptide
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
JP2016060710A (en) * 2014-09-17 2016-04-25 学校法人近畿大学 Peptide recognized by cell-mediated immunity, and pharmaceutical agent using it
JP2016065027A (en) * 2014-09-26 2016-04-28 学校法人近畿大学 Ezh2-derived peptide useful for cancer vaccine therapy to hla-a3 supertype allele positive prostate cancer patient
EP3360886A4 (en) * 2015-10-08 2019-06-12 Oncotherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
WO2020004622A1 (en) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 Antitumor agent and evaluation method thereof
WO2021132550A1 (en) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 Post-operation adjuvant therapy agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARASHIMA N ET AL: "Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T Lymphocytes of cancer patients with distant metastases", EUR. J. IMMUNOL, vol. 31, no. 2, 2001, pages 323 - 332, XP002212358 *
IMAI N ET AL: "Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases", INT. J. CANCER, vol. 94, no. 2, 2001, pages 237 - 242, XP002212565 *
MATSUEDA S ET AL: "Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles", CLIN. CANCER RES., vol. 11, no. 19, 2005, pages 6933 - 6943, XP003004983 *
MINAMI T ET AL: "Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles", CANCER IMMUNOL. IMMUNOTHER, vol. 56, no. 5, May 2007 (2007-05-01), pages 689 - 698, XP019489780 *
NAITO M ET AL: "Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles", BR. J. CANCER, vol. 97, no. 12, 2007, pages 1648 - 1654 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642900B2 (en) 2007-09-18 2017-05-09 Green Peptide Co., Ltd. CTL inducer composition
US9102715B2 (en) 2007-09-18 2015-08-11 Green Peptide Co., Ltd. CTL inducer composition
JP2017171678A (en) * 2013-10-21 2017-09-28 大鵬薬品工業株式会社 Novel four ctl epitope-joined peptide
US10137183B2 (en) 2013-10-21 2018-11-27 Taiho Pharmaceutical Co., Ltd. Peptide compositions having 4 linked CTL epitopes and uses thereof
CN105658673A (en) * 2013-10-21 2016-06-08 大鹏药品工业株式会社 Novel four-CTL epitope-joined peptide
JPWO2015060235A1 (en) * 2013-10-21 2017-03-09 大鵬薬品工業株式会社 Novel CTL epitope 4-linked peptide
CN105658673B (en) * 2013-10-21 2019-07-26 大鹏药品工业株式会社 The peptide of the novel CTL epitope with 4 connections
AU2014337643B2 (en) * 2013-10-21 2017-07-13 Taiho Pharmaceutical Co., Ltd. Novel four-CTL epitope-joined peptide
WO2015060235A1 (en) * 2013-10-21 2015-04-30 大鵬薬品工業株式会社 Novel four-ctl epitope-joined peptide
JP2016060710A (en) * 2014-09-17 2016-04-25 学校法人近畿大学 Peptide recognized by cell-mediated immunity, and pharmaceutical agent using it
JP2016065027A (en) * 2014-09-26 2016-04-28 学校法人近畿大学 Ezh2-derived peptide useful for cancer vaccine therapy to hla-a3 supertype allele positive prostate cancer patient
EP3360886A4 (en) * 2015-10-08 2019-06-12 Oncotherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
AU2016335731B2 (en) * 2015-10-08 2021-05-06 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
US11242365B2 (en) 2015-10-08 2022-02-08 Oncotherapy Science, Inc. FOXM1-derived peptide, and vaccine including same
EP4219525A3 (en) * 2015-10-08 2023-09-27 OncoTherapy Science, Inc. Foxm1-derived peptide, and vaccine including same
WO2020004622A1 (en) 2018-06-29 2020-01-02 大鵬薬品工業株式会社 Antitumor agent and evaluation method thereof
WO2021132550A1 (en) 2019-12-26 2021-07-01 大鵬薬品工業株式会社 Post-operation adjuvant therapy agent

Also Published As

Publication number Publication date
JP4972691B2 (en) 2012-07-11
JPWO2009022652A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2009022652A1 (en) Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
WO2006081826A3 (en) Survivin peptide vaccine
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
PH12014501083A1 (en) Anticancer fusion protein
MX2013006213A (en) Anticancer fusion protein.
MX2010005651A (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof.
WO2009038026A1 (en) Ctl inducer composition
HK1144305A1 (en) Cancer antigen peptides derived from wt1 wt1
WO2008087186A3 (en) Peptides for use in the treatment of obesity
WO2009025196A1 (en) Foxm1 peptide and medicinal agent comprising the same
DK2137301T3 (en) Adenovirus with mutations in the endoplasmic reticulum retention domain of the E3-19K protein and their use in cancer treatment
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
CL2007002382A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of skin cancer.
WO2011073215A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2008087188A3 (en) Peptides for use in the treatment of obesity
WO2008129422A8 (en) Demannosylated recombinant factor viii for the treatment of patients with haemophilia a
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
MX337756B (en) Hig2 and urlc10 epitope peptide and vaccines containing the same.
NZ599670A (en) Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
NZ594198A (en) Neil3 peptides and vaccines including the same
WO2005123760A3 (en) Treating cancer
MX2011013972A (en) Novel peptide and use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827222

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009528113

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08827222

Country of ref document: EP

Kind code of ref document: A1